Differential effect of drug interference in immunogenicity assays

Journal of Immunological Methods

Volumn 372, Issue 1-2, 2011, Pages 196-203

  Hart, Margreet H ^a   de Vrieze, Henk ^b   Wouters, Diana ^a   Wolbink, Gerrit Jan ^a,b   Killestein, Joep ^c   de Groot, Els R ^a   Aarden, Lucien A ^a   Rispens, Theo ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostics ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Bridging elisa; Drug interference; IgG4; Immunogenicity; Radioimmunoassay

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; BRIDGING ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG COMPETITION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; COHORT STUDIES; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; PROSPECTIVE STUDIES;

EID: 80052505451     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.07.019     Document Type: Article

References (25)

1. Aalberse R.C., van der Gaag R., van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J. Immunol. 1983, 130:722.
2. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 2009, 39:469.
3. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008, 20:431.
4. Allez M., Karmiris K., Louis E., Van A.G., Ben-Horin S., Klein A., Van der Woude J., Baert F., Eliakim R., Katsanos K., Brynskov J., Steinwurz F., Danese S., Vermeire S., Teillaud J.L., Lemann M., Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns. Colitis. 2010, 4:355.
5. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:921.
6. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10:345.
7. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 2007, 327:10.
8. Damen C.W., de Groot E.R., Heij M., Boss D.S., Schellens J.H., Rosing H., Beijnen J.H., Aarden L.A. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Anal. Biochem. 2009, 391:114.
9. de Vries M.K., Brouwer E., van der Horst-Bruinsma I.E., Spoorenberg A., Van Denderen J.C., Jamnitski A., Nurmohamed M.T., Dijkmans B.A., Aarden L.A., Wolbink G.J. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann. Rheum. Dis. 2009, 68:1787.
10. Lofgren J.A., Wala I., Koren E., Swanson S.J., Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods 2006, 308:101.
11. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 2007, 178:7467.
12. Nechansky A. HAHA-nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J. Pharm. Biomed. Anal. 2010, 51:252.
13. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 2005, 304:189.
14. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 2008, 20:460.
15. Rispens T., van L.A., Vennegoor A., Killestein J., Aalberse R.C., Wolbink G.J., Aarden L.A. Measurement of serum levels of natalizumab, an IgG4 therapeutic monoclonal antibody. Anal. Biochem. 2011, 411:271.
16. Schmidt E., Hennig K., Mengede C., Zillikens D., Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin. Immunol. 2009, 132:334.
17. Shapiro R.I., Plavina T., Schlain B.R., Pepinsky R.B., Garber E.A., Jarpe M., Hochman P.S., Wehner N.G., Bard F., Motter R., Yednock T.A., Taylor F.R. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri((R))) with endogenous IgG4. J. Pharm. Biomed. Anal. 2011, 55:168.
18. Sickert D., Kroeger K., Zickler C., Chokote E., Winkler B., Grenet J.M., Legay F., Zaar A. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J. Immunol. Methods 2008, 334:29.
19. Swann P.G., Tolnay M., Muthukkumar S., Shapiro M.A., Rellahan B.L., Clouse K.A. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 2008, 20:493.
20. Thurlings R.M., Teng O., Vos K., Gerlag D.M., Aarden L., Stapel S.O., van Laar J.M., Tak P.P., Wolbink G.J. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:409.
21. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554.
22. Van der Zee J.S., Van Swieten P., Aalberse R.C. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J. Immunol. 1986, 137:3566.
23. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods 2010, 362:82.
24. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., Romagnani S., Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657.
25. Zhong Z.D., Dinnogen S., Hokom M., Ray C., Weinreich D., Swanson S.J., Chirmule N. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 2010, 355:21.